25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Scandion Oncology A/S
Buy, Hold or Sell?

Let's analyze Scandion Oncology A/S together

I guess you are interested in Scandion Oncology A/S. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Scandion Oncology A/S. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Scandion Oncology A/S

I send you an email if I find something interesting about Scandion Oncology A/S.

1. Quick Overview

1.1. Quick analysis of Scandion Oncology A/S (30 sec.)










1.2. What can you expect buying and holding a share of Scandion Oncology A/S? (30 sec.)

How much money do you get?

How much money do you get?
kr0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
kr0.20
Expected worth in 1 year
kr0.06
How sure are you?
22.2%

+ What do you gain per year?

Total Gains per Share
kr-0.14
Return On Investment
-205.1%

For what price can you sell your share?

Current Price per Share
kr0.07
Expected price per share
kr0.065 - kr0.122
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Scandion Oncology A/S (5 min.)




Live pricePrice per Share (EOD)
kr0.07
Intrinsic Value Per Share
kr0.30 - kr0.52
Total Value Per Share
kr0.50 - kr0.73

2.2. Growth of Scandion Oncology A/S (5 min.)




Is Scandion Oncology A/S growing?

Current yearPrevious yearGrowGrow %
How rich?$4.3m$9.4m-$4.9m-111.1%

How much money is Scandion Oncology A/S making?

Current yearPrevious yearGrowGrow %
Making money-$1.2m-$2m$808.7k64.1%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Scandion Oncology A/S (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Scandion Oncology A/S?

Welcome investor! Scandion Oncology A/S's management wants to use your money to grow the business. In return you get a share of Scandion Oncology A/S.

First you should know what it really means to hold a share of Scandion Oncology A/S. And how you can make/lose money.

Speculation

The Price per Share of Scandion Oncology A/S is kr0.07. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Scandion Oncology A/S.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Scandion Oncology A/S, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is kr0.20. Based on the TTM, the Book Value Change Per Share is kr-0.04 per quarter. Based on the YOY, the Book Value Change Per Share is kr-0.03 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is kr0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Scandion Oncology A/S.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 kr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Share
Usd Eps0.00-6.2%-0.01-7.8%-0.01-12.7%-0.01-8.9%0.00-7.0%
Usd Book Value Change Per Share0.006.2%0.00-4.7%0.00-3.4%0.001.0%0.001.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.006.2%0.00-4.7%0.00-3.4%0.001.0%0.001.0%
Usd Price Per Share0.03-0.19-0.20-0.49-0.36-
Price to Earnings Ratio-1.52--8.29--6.08--16.41--12.16-
Price-to-Total Gains Ratio6.07--30.14--15.78--90.63--90.63-
Price to Book Ratio1.42-10.51-4.77-9.18-6.80-
Price-to-Total Gains Ratio6.07--30.14--15.78--90.63--90.63-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.00637
Number of shares156985
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.000.00
Usd Total Gains Per Share0.000.00
Gains per Quarter (156985 shares)-512.74114.18
Gains per Year (156985 shares)-2,050.97456.74
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-2051-20610457447
20-4102-41120913904
30-6153-6163013701361
40-8204-8214018271818
50-10255-10265022842275
60-12306-12316027402732
70-14357-14367031973189
80-16408-16418036543646
90-18459-18469041114103
100-20510-20520045674560

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.027.00.00.0%0.027.00.00.0%
Book Value Change Per Share1.03.00.025.0%2.010.00.016.7%4.016.00.020.0%6.020.01.022.2%6.020.01.022.2%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.027.00.0%0.00.027.00.0%
Total Gains per Share1.03.00.025.0%2.010.00.016.7%4.016.00.020.0%6.020.01.022.2%6.020.01.022.2%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Scandion Oncology A/S compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.048-0.036+175%-0.026+154%0.008+498%0.008+530%
Book Value Per Share--0.2050.212-4%0.449-54%0.430-52%0.326-37%
Current Ratio--4.1216.780-39%5.951-31%8.761-53%7.890-48%
Debt To Asset Ratio--0.2120.150+42%0.179+19%0.146+45%0.257-18%
Debt To Equity Ratio--0.2690.179+50%0.219+23%0.181+49%0.172+56%
Dividend Per Share----0%-0%-0%-0%
Eps---0.048-0.060+25%-0.098+105%-0.068+43%-0.054+13%
Free Cash Flow Per Share---0.026-0.054+109%-0.114+339%-0.069+166%-0.056+114%
Free Cash Flow To Equity Per Share--0.067-0.032+148%-0.044+166%0.013+405%0.011+532%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--0.522--------
Intrinsic Value_10Y_min--0.300--------
Intrinsic Value_1Y_max---0.304--------
Intrinsic Value_1Y_min---0.299--------
Intrinsic Value_3Y_max---0.642--------
Intrinsic Value_3Y_min---0.618--------
Intrinsic Value_5Y_max---0.652--------
Intrinsic Value_5Y_min---0.629--------
Market Cap16235029.440-314%67259407.680481658534.136-86%499401102.024-87%1248125870.448-95%924537681.813-93%
Net Profit Margin----0%-0%-0.0930%-0.0690%
Operating Margin----0%-0%-1.0210%-0.7560%
Operating Ratio----0%-0%20.716-100%15.345-100%
Pb Ratio0.342-314%1.41610.512-87%4.768-70%9.178-85%6.798-79%
Pe Ratio-0.366+76%-1.518-8.294+446%-6.078+300%-16.415+981%-12.159+701%
Price Per Share0.070-314%0.2902.077-86%2.153-87%5.382-95%3.986-93%
Price To Free Cash Flow Ratio-0.674+76%-2.794-8.468+203%-14.586+422%-19.343+592%-14.328+413%
Price To Total Gains Ratio1.464-314%6.065-30.141+597%-15.782+360%-90.629+1594%-90.629+1594%
Quick Ratio--3.2635.271-38%5.772-43%8.004-59%6.671-51%
Return On Assets---0.184-0.246+34%-0.170-8%-0.178-3%-0.260+41%
Return On Equity---0.233-0.287+23%-0.208-11%-0.216-7%-0.231-1%
Total Gains Per Share--0.048-0.036+175%-0.026+154%0.008+498%0.008+530%
Usd Book Value--4322858.7224484893.823-4%9469574.660-54%9074494.164-52%6882634.234-37%
Usd Book Value Change Per Share--0.004-0.003+175%-0.002+154%0.001+498%0.001+530%
Usd Book Value Per Share--0.0190.019-4%0.041-54%0.039-52%0.030-37%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.004-0.005+25%-0.009+105%-0.006+43%-0.005+13%
Usd Free Cash Flow---547690.598-1147223.987+109%-2402368.697+339%-1455353.254+166%-1172830.809+114%
Usd Free Cash Flow Per Share---0.002-0.005+109%-0.010+339%-0.006+166%-0.005+114%
Usd Free Cash Flow To Equity Per Share--0.006-0.003+148%-0.004+166%0.001+405%0.001+532%
Usd Market Cap1477387.679-314%6120606.09943830926.606-86%45445500.284-87%113579454.211-95%84132929.045-93%
Usd Price Per Share0.006-314%0.0260.189-86%0.196-87%0.490-95%0.363-93%
Usd Profit---1007874.504-1261777.563+25%-2070546.205+105%-1442161.733+43%-1143537.394+13%
Usd Revenue----0%-0%403.037-100%298.546-100%
Usd Total Gains Per Share--0.004-0.003+175%-0.002+154%0.001+498%0.001+530%
 EOD+2 -6MRQTTM+17 -12YOY+15 -145Y+16 -1510Y+18 -13

3.3 Fundamental Score

Let's check the fundamental score of Scandion Oncology A/S based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.366
Price to Book Ratio (EOD)Between0-10.342
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than13.263
Current Ratio (MRQ)Greater than14.121
Debt to Asset Ratio (MRQ)Less than10.212
Debt to Equity Ratio (MRQ)Less than10.269
Return on Equity (MRQ)Greater than0.15-0.233
Return on Assets (MRQ)Greater than0.05-0.184
Total5/10 (50.0%)

3.4 Technical Score

Let's check the technical score of Scandion Oncology A/S based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5027.903
Ma 20Greater thanMa 500.083
Ma 50Greater thanMa 1000.115
Ma 100Greater thanMa 2000.144
OpenGreater thanClose0.070
Total0/5 (0.0%)

4. In-depth Analysis

4.1 About Scandion Oncology A/S

Scandion Oncology A/S, a clinical-stage biotechnology company, discovers and develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase II clinical trial for the treatment of colorectal cancer; and in Phase I clinical trial for treating pancreatic cancer, as well as in preclinical studies for other cancer indications. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark.

Fundamental data was last updated by Penke on 2024-11-14 18:11:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Scandion Oncology A/S earns for each kr1 of revenue.

  • Above 10% is considered healthy but always compare Scandion Oncology A/S to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that kr0.00 for each kr1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Scandion Oncology A/S:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-9.3%+9.3%
5Y-9.3%10Y-6.9%-2.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--115.9%+115.9%
TTM--210.8%+210.8%
YOY--214.5%+214.5%
5Y-9.3%-342.2%+332.9%
10Y-6.9%-464.5%+457.6%
4.3.1.2. Return on Assets

Shows how efficient Scandion Oncology A/S is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Scandion Oncology A/S to the Biotechnology industry mean.
  • -18.4% Return on Assets means that Scandion Oncology A/S generated kr-0.18 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Scandion Oncology A/S:

  • The MRQ is -18.4%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -24.6%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-18.4%TTM-24.6%+6.3%
TTM-24.6%YOY-17.0%-7.6%
TTM-24.6%5Y-17.8%-6.8%
5Y-17.8%10Y-26.0%+8.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-18.4%-11.1%-7.3%
TTM-24.6%-11.7%-12.9%
YOY-17.0%-11.3%-5.7%
5Y-17.8%-12.7%-5.1%
10Y-26.0%-14.3%-11.7%
4.3.1.3. Return on Equity

Shows how efficient Scandion Oncology A/S is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Scandion Oncology A/S to the Biotechnology industry mean.
  • -23.3% Return on Equity means Scandion Oncology A/S generated kr-0.23 for each kr1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Scandion Oncology A/S:

  • The MRQ is -23.3%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -28.7%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-23.3%TTM-28.7%+5.4%
TTM-28.7%YOY-20.8%-7.9%
TTM-28.7%5Y-21.6%-7.1%
5Y-21.6%10Y-23.1%+1.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-23.3%-14.2%-9.1%
TTM-28.7%-15.8%-12.9%
YOY-20.8%-13.9%-6.9%
5Y-21.6%-18.5%-3.1%
10Y-23.1%-19.5%-3.6%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Scandion Oncology A/S.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Scandion Oncology A/S is operating .

  • Measures how much profit Scandion Oncology A/S makes for each kr1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Scandion Oncology A/S to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated kr0.00  for each kr1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Scandion Oncology A/S:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-102.1%+102.1%
5Y-102.1%10Y-75.6%-26.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--258.6%+258.6%
TTM--318.3%+318.3%
YOY--224.0%+224.0%
5Y-102.1%-386.5%+284.4%
10Y-75.6%-497.6%+422.0%
4.3.2.2. Operating Ratio

Measures how efficient Scandion Oncology A/S is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are kr0.00 for each kr1 in net sales.

Let's take a look of the Operating Ratio trends of Scandion Oncology A/S:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y20.716-20.716
5Y20.71610Y15.345+5.371
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.594-2.594
TTM-3.360-3.360
YOY-3.299-3.299
5Y20.7164.788+15.928
10Y15.3456.528+8.817
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Scandion Oncology A/S.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Scandion Oncology A/S is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 4.12 means the company has kr4.12 in assets for each kr1 in short-term debts.

Let's take a look of the Current Ratio trends of Scandion Oncology A/S:

  • The MRQ is 4.121. The company is very able to pay all its short-term debts. +2
  • The TTM is 6.780. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ4.121TTM6.780-2.660
TTM6.780YOY5.951+0.830
TTM6.7805Y8.761-1.981
5Y8.76110Y7.890+0.871
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.1213.658+0.463
TTM6.7803.874+2.906
YOY5.9514.672+1.279
5Y8.7615.960+2.801
10Y7.8906.277+1.613
4.4.3.2. Quick Ratio

Measures if Scandion Oncology A/S is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Scandion Oncology A/S to the Biotechnology industry mean.
  • A Quick Ratio of 3.26 means the company can pay off kr3.26 for each kr1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Scandion Oncology A/S:

  • The MRQ is 3.263. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 5.271. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ3.263TTM5.271-2.008
TTM5.271YOY5.772-0.501
TTM5.2715Y8.004-2.733
5Y8.00410Y6.671+1.333
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.2633.104+0.159
TTM5.2713.426+1.845
YOY5.7724.498+1.274
5Y8.0045.933+2.071
10Y6.6716.426+0.245
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Scandion Oncology A/S.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Scandion Oncology A/S assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Scandion Oncology A/S to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.21 means that Scandion Oncology A/S assets are financed with 21.2% credit (debt) and the remaining percentage (100% - 21.2%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Scandion Oncology A/S:

  • The MRQ is 0.212. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.150. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.212TTM0.150+0.062
TTM0.150YOY0.179-0.029
TTM0.1505Y0.146+0.004
5Y0.14610Y0.257-0.111
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2120.354-0.142
TTM0.1500.345-0.195
YOY0.1790.311-0.132
5Y0.1460.366-0.220
10Y0.2570.382-0.125
4.5.4.2. Debt to Equity Ratio

Measures if Scandion Oncology A/S is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Scandion Oncology A/S to the Biotechnology industry mean.
  • A Debt to Equity ratio of 26.9% means that company has kr0.27 debt for each kr1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Scandion Oncology A/S:

  • The MRQ is 0.269. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.179. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.269TTM0.179+0.090
TTM0.179YOY0.219-0.040
TTM0.1795Y0.181-0.001
5Y0.18110Y0.172+0.009
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2690.398-0.129
TTM0.1790.437-0.258
YOY0.2190.378-0.159
5Y0.1810.452-0.271
10Y0.1720.495-0.323
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every kr1 in earnings Scandion Oncology A/S generates.

  • Above 15 is considered overpriced but always compare Scandion Oncology A/S to the Biotechnology industry mean.
  • A PE ratio of -1.52 means the investor is paying kr-1.52 for every kr1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Scandion Oncology A/S:

  • The EOD is -0.366. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.518. Based on the earnings, the company is expensive. -2
  • The TTM is -8.294. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.366MRQ-1.518+1.152
MRQ-1.518TTM-8.294+6.776
TTM-8.294YOY-6.078-2.216
TTM-8.2945Y-16.415+8.121
5Y-16.41510Y-12.159-4.256
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.366-2.160+1.794
MRQ-1.518-2.428+0.910
TTM-8.294-3.145-5.149
YOY-6.078-3.304-2.774
5Y-16.415-6.080-10.335
10Y-12.159-6.625-5.534
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Scandion Oncology A/S:

  • The EOD is -0.674. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -2.794. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -8.468. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.674MRQ-2.794+2.119
MRQ-2.794TTM-8.468+5.675
TTM-8.468YOY-14.586+6.117
TTM-8.4685Y-19.343+10.874
5Y-19.34310Y-14.328-5.015
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.674-2.980+2.306
MRQ-2.794-3.295+0.501
TTM-8.468-3.682-4.786
YOY-14.586-4.523-10.063
5Y-19.343-8.162-11.181
10Y-14.328-9.239-5.089
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Scandion Oncology A/S is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.42 means the investor is paying kr1.42 for each kr1 in book value.

Let's take a look of the Price to Book Ratio trends of Scandion Oncology A/S:

  • The EOD is 0.342. Based on the equity, the company is cheap. +2
  • The MRQ is 1.416. Based on the equity, the company is underpriced. +1
  • The TTM is 10.512. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD0.342MRQ1.416-1.074
MRQ1.416TTM10.512-9.096
TTM10.512YOY4.768+5.744
TTM10.5125Y9.178+1.334
5Y9.17810Y6.798+2.379
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.3421.869-1.527
MRQ1.4162.027-0.611
TTM10.5122.365+8.147
YOY4.7682.419+2.349
5Y9.1783.668+5.510
10Y6.7984.362+2.436
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2024-06-30. Currency in DKK. All numbers in thousands.

Summary
Total Assets38,987
Total Liabilities8,260
Total Stockholder Equity30,727
 As reported
Total Liabilities 8,260
Total Stockholder Equity+ 30,727
Total Assets = 38,987

Assets

Total Assets38,987
Total Current Assets34,037
Long-term Assets4,950
Total Current Assets
Cash And Cash Equivalents 26,952
Other Current Assets 7,085
Total Current Assets  (as reported)34,037
Total Current Assets  (calculated)34,037
+/-0
Long-term Assets
Property Plant Equipment 378
Long-term Assets Other 4,572
Long-term Assets  (as reported)4,950
Long-term Assets  (calculated)4,950
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities8,260
Long-term Liabilities0
Total Stockholder Equity30,727
Total Current Liabilities
Short-term Debt 180
Accounts payable 1,939
Other Current Liabilities 6,141
Total Current Liabilities  (as reported)8,260
Total Current Liabilities  (calculated)8,260
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Common Stock17,047
Retained Earnings -219,611
Other Stockholders Equity 233,291
Total Stockholder Equity (as reported)30,727
Total Stockholder Equity (calculated)30,727
+/-0
Other
Capital Stock17,047
Cash and Short Term Investments 26,952
Common Stock Shares Outstanding 231,928
Liabilities and Stockholders Equity 38,987
Net Debt -26,772
Net Invested Capital 30,727
Net Working Capital 25,777
Property Plant and Equipment Gross 378
Short Long Term Debt Total 180



6.2. Balance Sheets Structured

Currency in DKK. All numbers in thousands.

 Trend2024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-30
> Total Assets 
0
1,962
0
1,320
1,777
13,563
11,537
7,808
23,157
19,903
16,323
13,937
11,338
186,408
153,885
144,556
129,545
116,219
101,259
87,728
106,474
89,401
73,873
60,186
50,832
34,560
26,637
38,987
38,98726,63734,56050,83260,18673,87389,401106,47487,728101,259116,219129,545144,556153,885186,40811,33813,93716,32319,90323,1577,80811,53713,5631,7771,32001,9620
   > Total Current Assets 
0
1,927
0
612
783
13,528
11,472
7,742
21,280
19,630
16,059
11,715
8,060
186,125
151,211
138,986
123,474
114,304
95,850
80,702
99,472
86,855
68,953
53,032
43,940
33,664
23,547
34,037
34,03723,54733,66443,94053,03268,95386,85599,47280,70295,850114,304123,474138,986151,211186,1258,06011,71516,05919,63021,2807,74211,47213,52878361201,9270
       Cash And Cash Equivalents 
0
1,638
0
327
544
7,662
5,281
3,160
18,028
15,421
11,013
7,276
7,505
5,814
145,216
131,542
117,360
105,710
87,965
72,667
91,362
77,605
60,185
45,709
36,330
26,520
16,956
26,952
26,95216,95626,52036,33045,70960,18577,60591,36272,66787,965105,710117,360131,542145,2165,8147,5057,27611,01315,42118,0283,1605,2817,66254432701,6380
       Net Receivables 
0
0
0
0
0
0
0
0
0
3,969
4,834
4,255
329
5,798
5,430
6,895
5,385
7,518
6,844
7,248
7,315
0
8,077
6,611
0
0
0
0
00006,6118,07707,3157,2486,8447,5185,3856,8955,4305,7983294,2554,8343,969000000000
       Other Current Assets 
0
290
0
284
238
5,866
6,190
4,582
3,252
4,209
0
4,440
0
174,318
5,995
7,444
6,114
8,594
7,885
8,035
8,110
9
9
7
8
7
-1
7,085
7,085-1787998,1108,0357,8858,5946,1147,4445,995174,31804,44004,2093,2524,5826,1905,86623828402900
   > Long-term Assets 
0
35
0
708
994
35
66
66
1,877
273
264
2,221
3,278
283
2,674
5,570
6,072
1,915
5,409
7,026
7,002
2,546
4,921
7,154
6,892
897
3,090
4,950
4,9503,0908976,8927,1544,9212,5467,0027,0265,4091,9156,0725,5702,6742833,2782,2212642731,8776666359947080350
       Property Plant Equipment 
0
0
0
0
0
0
0
0
0
171
162
154
145
136
127
268
284
1,601
1,450
1,236
1,212
2,256
2,011
1,766
1,144
649
487
378
3784876491,1441,7662,0112,2561,2121,2361,4501,601284268127136145154162171000000000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
1,966
3,032
0
2,399
5,302
-1
314
3,959
5,790
0
290
-1
5,388
0
-1
0
1
10-105,388-129005,7903,959314-15,3022,39903,0321,96600000000000
> Total Liabilities 
0
509
0
1,805
3,276
993
916
1,063
1,971
1,564
1,760
2,778
4,071
30,543
6,781
9,994
10,292
11,678
9,587
19,959
20,864
19,074
12,835
7,921
8,720
3,438
3,083
8,260
8,2603,0833,4388,7207,92112,83519,07420,86419,9599,58711,67810,2929,9946,78130,5434,0712,7781,7601,5641,9711,0639169933,2761,80505090
   > Total Current Liabilities 
0
509
0
1,805
3,276
993
916
1,063
1,971
1,459
1,530
2,353
4,063
30,026
6,264
9,986
10,284
11,094
8,293
18,069
19,710
18,254
12,135
6,377
7,887
3,438
3,083
8,260
8,2603,0833,4387,8876,37712,13518,25419,71018,0698,29311,09410,2849,9866,26430,0264,0632,3531,5301,4591,9711,0639169933,2761,80505090
       Short-term Debt 
0
0
0
0
800
0
0
0
0
1
0
0
0
316
0
0
0
723
748
305
374
776
701
603
116
499
269
180
180269499116603701776374305748723000316000100008000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000001000000000
       Accounts payable 
0
508
0
1,805
652
716
639
717
974
961
1,293
1,084
1,427
26,064
2,584
4,140
2,634
4,580
3,289
10,954
4,931
4,895
2,564
2,361
3,009
1,381
2,055
1,939
1,9392,0551,3813,0092,3612,5644,8954,93110,9543,2894,5802,6344,1402,58426,0641,4271,0841,2939619747176397166521,80505080
       Other Current Liabilities 
0
1
0
1
1,824
277
277
346
997
497
237
1,270
2,636
3,962
3,680
5,846
7,650
5,791
4,256
6,810
14,405
12,583
8,870
3,413
1,753
177
-1,296
6,141
6,141-1,2961771,7533,4138,87012,58314,4056,8104,2565,7917,6505,8463,6803,9622,6361,2702374979973462772771,8241010
   > Long-term Liabilities 
0
0
0
1,805
0
716
639
717
0
105
229
425
8
517
517
8
8
584
1,294
1,890
1,154
820
700
1,544
833
0
0
0
0008331,5447008201,1541,8901,294584885175178425229105071763971601,805000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
105
229
425
8
517
517
9
8
84
1,057
1,390
905
0
-1
941
0
0
0
0
0000941-109051,3901,05784895175178425229105000000000
> Total Stockholder Equity
0
1,453
0
-486
-1,499
12,570
10,622
6,745
21,186
18,338
14,564
11,159
7,267
155,865
147,104
134,562
119,253
104,541
91,672
67,769
85,610
70,327
61,038
52,265
42,112
31,122
23,554
30,727
30,72723,55431,12242,11252,26561,03870,32785,61067,76991,672104,541119,253134,562147,104155,8657,26711,15914,56418,33821,1866,74510,62212,570-1,499-48601,4530
   Common Stock
0
540
0
549
549
875
875
875
1,400
1,400
1,400
1,400
1,400
2,362
2,362
2,363
2,362
2,362
2,362
2,362
2,992
2,992
2,992
2,992
2,992
2,992
2,992
17,047
17,0472,9922,9922,9922,9922,9922,9922,9922,3622,3622,3622,3622,3632,3622,3621,4001,4001,4001,4001,40087587587554954905400
   Retained Earnings Total Equity0000000000000000000000000000
   Accumulated Other Comprehensive Income 000000000000-1000000000000000
   Capital Surplus 0000000000000000000000000000
   Treasury Stock0000000000000000000000000000
   Other Stockholders Equity 
0
1,926
0
2,367
2,367
20,890
20,890
20,890
41,058
0
0
0
0
191,151
191,151
191,151
191,151
191,152
191,152
191,152
232,985
233,008
233,008
233,008
233,008
233,008
233,008
233,291
233,291233,008233,008233,008233,008233,008233,008232,985191,152191,152191,152191,151191,151191,151191,151000041,05820,89020,89020,8902,3672,36701,9260



6.3. Balance Sheets

Currency in DKK. All numbers in thousands.




6.4. Cash Flows

Currency in DKK. All numbers in thousands.




6.5. Income Statements

Currency in DKK. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in DKK. All numbers in thousands.

Gross Profit (+$)
totalRevenue0
Cost of Revenue--
Gross Profit-0
 
Operating Income (+$)
Gross Profit-
Operating Expense-45,357
Operating Income-45,357-45,357
 
Operating Expense (+$)
Research Development31,851
Selling General Administrative13,952
Selling And Marketing Expenses-
Operating Expense45,35745,803
 
Net Interest Income (+$)
Interest Income132
Interest Expense-38
Other Finance Cost-0
Net Interest Income94
 
Pretax Income (+$)
Operating Income-45,357
Net Interest Income94
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-44,704-46,010
EBIT - interestExpense = -45,841
-33,704
-39,166
Interest Expense38
Earnings Before Interest and Taxes (EBIT)-45,803-44,666
Earnings Before Interest and Taxes (EBITDA)-45,532
 
After tax Income (+$)
Income Before Tax-44,704
Tax Provision--5,500
Net Income From Continuing Ops-39,204-39,204
Net Income-39,204
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses45,357
Total Other Income/Expenses Net653-94
 

Technical Analysis of Scandion Oncology A/S
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Scandion Oncology A/S. The general trend of Scandion Oncology A/S is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Scandion Oncology A/S's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Scandion Oncology A/S.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 0.088 < 0.122 < 0.122.

The bearish price targets are: 0.065.

Tweet this
Scandion Oncology A/S Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Scandion Oncology A/S. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Scandion Oncology A/S Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Scandion Oncology A/S. The current macd is -0.0128182.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Scandion Oncology A/S price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Scandion Oncology A/S. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Scandion Oncology A/S price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Scandion Oncology A/S Daily Moving Average Convergence/Divergence (MACD) ChartScandion Oncology A/S Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Scandion Oncology A/S. The current adx is 48.07.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -4/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Scandion Oncology A/S shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bearish trend. The ADX is trending up, so the bearish trend is strengthening.
Scandion Oncology A/S Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Scandion Oncology A/S. The current sar is 0.08763.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Scandion Oncology A/S Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Scandion Oncology A/S. The current rsi is 27.90. The current phase is Oversold in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 0/(-13 +13).

  • Oversold in bear market: Short-term excessive selling, potential for relief rally. Be cautious, consider taking short-term long positions. +1
  • Trending down: The RSI is trending down. -1
Scandion Oncology A/S Daily Relative Strength Index (RSI) ChartScandion Oncology A/S Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Scandion Oncology A/S. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Scandion Oncology A/S price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Scandion Oncology A/S Daily Stochastic Oscillator ChartScandion Oncology A/S Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Scandion Oncology A/S. The current cci is -79.66896002.

Scandion Oncology A/S Daily Commodity Channel Index (CCI) ChartScandion Oncology A/S Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Scandion Oncology A/S. The current cmo is -45.53819749.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Scandion Oncology A/S Daily Chande Momentum Oscillator (CMO) ChartScandion Oncology A/S Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Scandion Oncology A/S. The current willr is -84.61538462.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Scandion Oncology A/S Daily Williams %R ChartScandion Oncology A/S Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Scandion Oncology A/S.

Scandion Oncology A/S Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Scandion Oncology A/S. The current atr is 0.01082081.

Scandion Oncology A/S Daily Average True Range (ATR) ChartScandion Oncology A/S Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Scandion Oncology A/S. The current obv is -51,064,567.

Scandion Oncology A/S Daily On-Balance Volume (OBV) ChartScandion Oncology A/S Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Scandion Oncology A/S. The current mfi is 29.51.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Scandion Oncology A/S Daily Money Flow Index (MFI) ChartScandion Oncology A/S Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Scandion Oncology A/S.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-07-11RSI LONG ENTRY SHORT CLOSE30 crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-07-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-07-17SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-07-18CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-07-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-24STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-31STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-02STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-08-06MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-08-08MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-08-09MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-08-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-13CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-08-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-19STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-08-20CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-08-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-26CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-08-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-30STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-04STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-09CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-09-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-12CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-09-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-09-18DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-20CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-09-23STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-25STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-09-27WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-09-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-02CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-10-08WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-09DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-11WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-10-16CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-10-17STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-21CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-10-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-29STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-10-31WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-01BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-04ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-07BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-11-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-11-18MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-11-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-25SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-11-26WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside

6.3. Candlestick Patterns

Scandion Oncology A/S Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Scandion Oncology A/S based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5027.903
Ma 20Greater thanMa 500.083
Ma 50Greater thanMa 1000.115
Ma 100Greater thanMa 2000.144
OpenGreater thanClose0.070
Total0/5 (0.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Scandion Oncology A/S with someone you think should read this too:
  • Are you bullish or bearish on Scandion Oncology A/S? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Scandion Oncology A/S? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Scandion Oncology A/S

I send you an email if I find something interesting about Scandion Oncology A/S.


Comments

How you think about this?

Leave a comment

Stay informed about Scandion Oncology A/S.

Receive notifications about Scandion Oncology A/S in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.